Research programme: antivirals - Arisyn Therapeutics

Drug Profile

Research programme: antivirals - Arisyn Therapeutics

Alternative Names: ATI-0409; ATI-0607; ATI-0655; ATI-0810; ATI-5488; PG 301209; PG-301995

Latest Information Update: 12 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Procter & Gamble
  • Developer Arisyn Therapeutics
  • Class Small molecules
  • Mechanism of Action Hepatitis B virus replication inhibitors; Hepatitis C virus replication inhibitors; HIV replication inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Influenza virus infections

Most Recent Events

  • 15 Sep 2009 Pharmacodynamics data from in vitro studies in Hepatitis C presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
  • 14 May 2009 Pharmacodynamics data from a preclinical trial of ATI 0810 in Hepatitis C released by ImQuest and Arisyn
  • 24 Nov 2008 Compounds from this programme are available for licensing (http://www.arisyn.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top